Comparison of diagnosing and staging accuracy of PET (CT) and MIBG on patients with neuroblastoma: Systemic review and meta-analysis

• Published in: Current medical science 2017-10, Vol.37 (5), p.649-660
• Main Authors: Xia, Jia, Zhang, Hang, Hu, Qun, Liu, Shuang-you, Zhang, Liu-qing, Zhang, Ai, Zhang, Xiao-ling, Wang, Ya-qin, Liu, Ai-guo
• Format: Article
• Language: English
• Subjects: Medicine; Medicine & Public Health
• ISSN: 2096-5230; 1672-0733; 2523-899X; 1993-1352
• DOI: 10.1007/s11596-017-1785-x

Summary To perform a systemic review and meta-analysis of the diagnostic accuracy of PET (CT) and metaiodobenzylguanidine (MIBG) for diagnosing neuroblastoma (NB), electronic databases were searched as well as relevant references and conference proceedings. The diagnostic accuracy of MIBG and PET (CT) was calculated for NB, primary NB, and relapse/metastasis of NB based on their sensitivity, specificity, and area under the summary receiver operating characteristic curve (AUSROC) in terms of per-lesion and per-patient data. A total of 40 eligible studies comprising 1134 patients with 939 NB lesions were considered for the meta-analysis. For the staging of NB, the per-lesion AUSROC value of MIBG was lower than that of PET (CT) [0.8064±0.0414 vs. 0.9366±0.0166 ( P